JAC Advance Access originally published online on October 12, 2005
Journal of Antimicrobial Chemotherapy 2005 56(5):990; doi:10.1093/jac/dki358
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe
J Antimicrob Chemother 2005; 55: 717
There is an error in Table 2 of this article. The percentage susceptibility of Klebsiella pneumoniae in Northern Europe to meropenem 1 g every 8 h should be 99% (not 88%). The authors apologize for this error.
![]()
CiteULike
Connotea
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||